Estrogen therapy changes bone at the cellular and mineral-density level, but it does not reshape the broader skeletal frame in adults whose growth plates have already closed. For trans women who begin hormone therapy after puberty is complete, estrogen slows bone breakdown, can stabilize or modestly improve bone mineral density, and shifts bone-turnover markers in directions associated with lower resorption. What it cannot do is narrow shoulders, shrink the ribcage, or widen the pelvis, because those dimensions are set by the skeleton’s growth during the original puberty. The distinction between bone density and bone geometry is the crux of the answer, and it matters for both expectations and health monitoring.
Where Trans Women Start Before Hormones
One of the more surprising findings in the research is that many trans women already have lower bone density than comparable cisgender men before they ever start estrogen. Studies have consistently observed low bone density in trans women prior to gender-affirming hormone therapy, while trans men generally do not show the same pattern before testosterone.1PubMed Central. Bone Health in the Transgender Population One prospective study found that, compared with cisgender male controls, trans women had lower areal bone mineral density at every measured site, smaller cortical bone, and lower lean body mass and muscle strength before any cross-sex hormone use.2PubMed. Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study
The reasons for this pre-treatment deficit are not entirely settled. Researchers suspect it relates to lower physical activity levels, less sun exposure, lower body weight, and possibly years of lower testosterone effect in some individuals. Whatever the cause, it means that when trans women begin estrogen, they are not starting from the same bone-density baseline as the average cisgender man. That matters for interpreting what hormone therapy does next.
How Estrogen Protects Bone at the Cellular Level
Estrogen acts on bone through several cell types at once. It directly influences the cells that build bone (osteoblasts), the cells embedded within mature bone that sense mechanical strain (osteocytes), and the cells that break bone down (osteoclasts). The net effect is a slowdown in bone remodeling, a decrease in bone resorption, and support for ongoing bone formation.3PubMed Central. Estrogen and the skeleton In plainer terms, estrogen tells the demolition crew to ease up while letting the construction crew keep working. It also reduces the number of active osteoclasts, an effect thought to be driven partly through inflammatory signaling molecules in the bone marrow.4PubMed. Estrogen and bone metabolism
This is the same mechanism by which estrogen protects bone in cisgender women throughout their reproductive years and the same reason postmenopausal bone loss accelerates when estrogen levels drop. For trans women, introducing pharmacologic estrogen activates these protective pathways in a skeleton that may have been running with relatively less estrogenic influence for years.
What Happens to Bone Density on Hormone Therapy
The reassuring headline from the research is that bone mineral density generally holds steady or improves once trans women are on stable estrogen therapy. A study that followed 46 trans women over roughly two and a half years of hormone treatment found that bone mineral density remained stable throughout, even as body composition shifted toward more fat mass and less lean muscle.5PubMed. Impact of cross-sex hormone therapy on bone mineral density and body composition in transwomen Multiple reviews echo this pattern: with pharmacologic estrogen, many studies show stable or improving bone density in trans women.1PubMed Central. Bone Health in the Transgender Population
Bone-turnover markers tell a similar story. After one year of hormone therapy in trans women, markers of bone breakdown dropped, with resorption markers declining by roughly 11% and bone-formation markers shifting in directions consistent with lower turnover overall.6Journal of Bone and Mineral Research. Gender‐Affirming Hormone Treatment Decreases Bone Turnover in Transwomen and Older Transmen In practical terms, the bone is being chewed away less aggressively, which is exactly what you’d want to see.
Bone Microarchitecture Tells a More Complicated Story
Standard bone density scans measure mineral packed into a given area, but they don’t reveal much about the internal architecture of bone: the thickness of the outer shell (cortex), the spacing of the internal lattice (trabeculae), or the porosity of the cortical bone. When researchers used high-resolution imaging to look at these finer details in trans women who had been on hormones, the picture was less straightforward.
Compared with cisgender men, trans women showed thinner cortical bone, greater cortical porosity, and a trabecular network that was sparser with wider spacing between the internal struts. The trabecular bone volume fraction was lower, and the individual trabeculae, while fewer in number, were actually thicker than those in cisgender men.7Journal of Bone and Mineral Research. Bone Microarchitecture in Transgender Adults: A Cross‐Sectional Study This pattern looks somewhat like what you’d see in early osteoporotic changes in cisgender populations: the body compensates for losing some trabeculae by thickening the ones that remain, but overall structural integrity still takes a hit.
Whether these microarchitectural differences translate into meaningfully higher fracture risk is still being studied. The cross-sectional nature of most available data makes it hard to say whether these changes are caused by hormone therapy, whether they reflect the lower baseline density trans women started with, or whether they result from a period of low sex-hormone exposure before or during the transition process.
The Skeletal Frame Does Not Change in Adults
This is probably the area where expectations and biology clash most sharply. Estrogen cannot narrow an adult’s shoulders, slim the ribcage, or widen the hips. Those dimensions are determined by how bone grew during the original puberty, and once the growth plates fuse, the overall geometry is locked in. A recent study examining skeletal dimensions in transgender individuals confirmed this directly: hormonal treatment could alter shoulder width toward the affirmed gender only in individuals who started treatment during early puberty, when significant growth potential remained. Once shoulder width had increased during puberty, the change was irreversible.8PubMed Central. Shaping the Skeleton: Impact of GnRH Analogue and Sex Hormone Therapy on Skeletal Dimensions in Transgender Individuals
This does not mean hormone therapy has zero visible effect on body shape. Fat redistribution under estrogen’s influence shifts tissue toward the hips, thighs, and breasts, which can create a dramatically different silhouette even when the underlying bones haven’t changed. Muscle mass also decreases, particularly in the upper body, which can make the shoulders appear proportionally smaller even though the bone itself is the same width. The visual changes are real; they’re just happening in soft tissue, not in the skeleton.
Why Starting Age Matters So Much
The age at which someone begins gender-affirming treatment creates very different bone trajectories. For adolescents who receive puberty blockers (GnRH agonists) before starting estrogen, there is a period where both testosterone and estrogen are suppressed, and neither sex steroid is doing its usual job of driving bone accrual. Research consistently indicates that long-term puberty suppression has a negative impact on bone mineral density, particularly at the lumbar spine, which is only partially restored after sex steroids are later introduced.9PubMed Central. Impact of gender-affirming treatment on bone health in transgender and gender diverse youth
A study tracking transgender adolescents through puberty suppression and subsequent hormone therapy found that bone density z-scores decreased during the suppression phase. Among those assigned male at birth, lumbar spine z-scores after long-term gender-affirming hormones still averaged well below zero, indicating density remained lower than expected for their age.10PubMed Central. Bone Mineral Density in Transgender Adolescents Treated With Puberty Suppression and Subsequent Gender-Affirming Hormones The hip and femoral neck recovered more fully than the spine, but the lumbar spine deficit lingered.
The tradeoff is real. Early intervention allows changes to skeletal geometry that are impossible later, such as shifts in shoulder width and potentially more feminine pelvic proportions. But the gap in sex-steroid exposure during suppression leaves a bone-density debt that may not fully resolve. Whether that debt matters clinically over a lifetime is still being tracked, because the cohorts are young and the follow-up periods are relatively short.
Bone Marrow Changes During Puberty Suppression
A less-discussed effect of suppressing sex steroids in adolescence is what happens inside the bone marrow itself. Sex steroids promote the development of bone-building cells and inhibit the formation of fat cells within the marrow. When those hormones are suppressed, the balance tips toward more marrow fat and less bone formation. A pilot study in transgender and gender-nonconforming youth undergoing puberty suppression observed increased bone marrow fat alongside a lack of expected bone accrual, a pattern consistent with the known role of estrogen and testosterone in steering marrow stem cells toward bone rather than fat.11PubMed Central. Changes in Bone Marrow Adipose Tissue in Transgender and Gender Non-Conforming Youth Undergoing Pubertal Suppression: A Pilot Study This effect is a concern mostly during the suppression window itself and appears to reverse once sex hormones are introduced, but it underscores why the timing and duration of puberty suppression matter for bone health.
Fracture Risk in Trans Women
Bone density is clinically interesting, but what most people actually care about is whether they’ll break a bone. A large nationwide cohort study in the Netherlands provides the best available data on this. Among trans women younger than 50, fracture rates were similar to those in cisgender men and only slightly higher than in cisgender women; the difference was not statistically significant. Among trans women aged 50 and older, the fracture rate was about 4.4%, roughly double the rate in age-matched cisgender men (about 2.4%) but almost identical to the rate in age-matched cisgender women (about 4.2%).12PubMed Central. Fracture Risk in Trans Women and Trans Men Using Long‐Term Gender‐Affirming Hormonal Treatment: A Nationwide Cohort Study
That finding is nuanced and worth sitting with. Younger trans women do not appear to have elevated fracture risk compared with cisgender men. Older trans women have fracture rates that match those of cisgender women but are higher than those of cisgender men. In short, the fracture profile shifts toward what you’d expect for women of the same age. Earlier, shorter-term prospective trials had not detected significant fracture differences, likely because the study periods weren’t long enough or the sample sizes weren’t large enough to capture what is a relatively uncommon event.13PubMed Central. Osteoporosis and Bone Health in Transgender Persons
Does the Type of Estrogen Matter
Trans women take estrogen in several forms: oral pills, transdermal patches, intramuscular injections, and occasionally sublingual tablets. A reasonable question is whether the delivery method affects bone outcomes. One study comparing trans women on transdermal versus oral estrogen found no significant differences in bone size or density between the two groups.14PubMed. Prevalence of low bone mass in relation to estrogen treatment and body composition in male-to-female transsexual persons A narrative review confirmed that no head-to-head studies have compared clinical bone health outcomes across different hormone regimens in trans adults.15The Journal of Applied Laboratory Medicine. Gender-Affirming Hormone Therapy and Bone Health: Do Different Regimens Influence Outcomes in Transgender Adults? A Narrative Review and Call for Future Studies
This is a gap in the evidence, not a reassurance that all routes are equivalent. Different delivery methods produce different estrogen-level profiles throughout the day, different ratios of estrogen metabolites, and different effects on liver-mediated proteins. It is plausible that one route could outperform another for bone outcomes, but the data simply don’t exist yet to say so. In practice, most clinicians choose the route based on cardiovascular safety, patient preference, and ease of maintaining steady hormone levels rather than on bone-specific considerations.
When Screening and Monitoring Make Sense
The International Society for Clinical Densitometry issued a position statement clarifying when bone density scanning is warranted for transgender individuals. The core message: as long as someone is on standard gender-affirming hormone treatment, bone mineral density should remain stable or increase, so there is no reason to monitor for bone loss purely because someone is transgender. However, anyone who has experienced a substantial period without adequate sex hormones, roughly more than a year of hypogonadism, should be considered for a baseline bone density scan, because that gap can result in bone loss or failure to accrue bone normally.16PubMed. Bone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position
The guidelines also address a practical question that comes up in radiology departments: which reference data set should be used to interpret the scan? The recommendation is to use the reference data matching the person’s gender identity. So for a trans woman, the scan results should be compared against female norms. If there’s any ambiguity or if the individual or their provider requests it, both male and female reference scores can be provided for comparison.16PubMed. Bone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position
This matters because a trans woman’s z-score compared against male norms might look alarmingly low, while the same measurement compared against female norms might fall within a normal range. Using the wrong reference population can lead to unnecessary alarm or, conversely, false reassurance.
Lifestyle Factors That Interact With Bone Health
Hormones don’t act in a vacuum. A large study following trans individuals from adolescence into adulthood found that higher BMI and adequate vitamin D levels were positively associated with bone mineral density at multiple skeletal sites. Smoking, whether current or former, was associated with lower density at the hip and femoral neck.17The Lancet Regional Health – Europe. Effects of gender-affirming hormone therapy from adolescence to adulthood on bone mineral density, body composition and muscle strength None of this is unique to trans women; these same factors drive bone health in everyone. But because trans women may be starting from a lower baseline, the amplifying effect of vitamin D deficiency or smoking could be proportionally more consequential.
Weight-bearing exercise, calcium intake, and avoiding excessive alcohol are the same unglamorous recommendations that apply broadly to bone health. If you’re on estrogen therapy and concerned about your bones, the most effective thing you can do beyond staying on your hormones is to keep vitamin D levels adequate, stay active with some form of resistance or impact exercise, and not smoke. These factors are modifiable in ways that bone geometry is not, and the evidence suggests they matter at every skeletal site.
The Risk Window of Inconsistent Hormone Use
Periods without adequate sex hormones are a recurring concern in the research. This can happen for several reasons: stopping hormones due to cost or access barriers, surgical removal of the gonads without consistent hormone replacement afterward, or the gap between puberty suppression and starting estrogen in adolescents. The ISCD guidelines flag any period of hypogonadism longer than about a year as a reason to check bone density.16PubMed. Bone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position Without either testosterone or estrogen circulating at meaningful levels, bone resorption outpaces formation, and density drops. This is the same biology that drives postmenopausal osteoporosis in cisgender women and the less well-known phenomenon of bone loss in cisgender men with very low testosterone.
For trans women who have had an orchiectomy, estrogen therapy becomes the sole source of sex steroids for bone protection. If hormones are interrupted for any reason after gonadectomy, there’s no fallback hormonal signal to maintain bone. This makes consistent hormone access a bone-health issue, not just an identity-related one.
Facial Bone and Other Persistent Misconceptions
A common misconception is that estrogen therapy will gradually reshape facial bones, making the brow ridge less prominent or the jaw narrower. There is no evidence that this occurs in adults. Facial bone remodeling of that kind would require actual bone resorption at specific sites, and while bone does remodel throughout life, it does so at a pace far too slow and unpatterned to produce visible changes in facial contour from hormone therapy alone. The facial changes trans women notice on estrogen, softer-looking features, fuller cheeks, are driven almost entirely by fat redistribution and skin changes, not by the underlying bone moving.
Another persistent misconception is that estrogen “weakens” bone. The data show the opposite: estrogen is bone-protective, and bone density in trans women on stable therapy generally holds steady or improves. The concern is not that estrogen harms bone; it is that gaps in sex-hormone exposure, whether before starting therapy, during puberty suppression, or from inconsistent use, leave bone vulnerable. The hormone itself is part of the solution, not the problem.
A subtler misunderstanding involves conflating bone density with bone strength. As the microarchitecture data show, you can have reasonable density readings while the internal structure of the bone, its porosity and trabecular spacing, tells a less optimistic story. Standard bone density scans are useful but imperfect predictors of fracture risk, and this is true in cisgender populations as well. For trans women, the limited data on microarchitecture suggest that density scans alone may not capture the full picture, though it remains unclear whether the microarchitectural differences observed actually translate into more fractures beyond what the density numbers would predict.